BiotechTube

Atropine + Physostigmine + Placebo Sodium

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Insulin Resistance

Conditions

Insulin Resistance

Trial Timeline

May 1, 2007 → Nov 1, 2008

NCT ID
NCT00689208

About Atropine + Physostigmine + Placebo Sodium

Atropine + Physostigmine + Placebo Sodium is a phase 1 stage product being developed by AstraZeneca for Insulin Resistance. The current trial status is completed. This product is registered under clinical trial identifier NCT00689208. Target conditions include Insulin Resistance.

What happened to similar drugs?

8 of 20 similar drugs in Insulin Resistance were approved

Approved (8) Terminated (1) Active (12)
✅SaxagliptinAstraZenecaApproved
✅sitagliptinMerckApproved
✅simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
✅NateglinideNovartisApproved
✅Liraglutide or PlaceboNovo NordiskApproved
✅Liraglutide + Sugar PillNovo NordiskApproved
✅Glucovance (metformin HCl/glyburide) + or Metformin HCl alone + or Glyburide alone.Bristol Myers SquibbApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00689208Phase 1Completed

Competing Products

20 competing products in Insulin Resistance

See all competitors
ProductCompanyStageHype Score
naveglitazarEli LillyPhase 2
35
AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
40
Dapagliflozin 10 mg + Placebo tabletAstraZenecaPhase 3
40
Placebo 0.01 mL + Placebo 0.02 mL + Placebo 0.03 mL + Placebo 0.04 mL + AC2993 2.5 mcg + AC2993 5.0 mcg + AC2993 7.5 mcg + AC2993 10.0 mcgAstraZenecaPhase 2
35
SaxagliptinAstraZenecaApproved
43
AC2993 + AC2993 + Placebo + PlaceboAstraZenecaPhase 3
40
Pramlintide acetateAstraZenecaPhase 2
35
sitagliptin + Comparator: glimepiride + open-label metforminMerckPhase 3
40
sitagliptinMerckApproved
35
sitagliptin phosphateMerckPhase 3
40
MK-1006 + PlaceboMerckPhase 1
29
Comparator: Placebo + Sitagliptin + VogliboseMerckPhase 3
40
sitagliptin phosphate + Comparator: metformin + Comparator: metformin + Comparator: Antidiabetic Standard of CareMerckPhase 3
40
Placebo + MK-0941MerckPhase 1
29
Placebo + PrednisoloneMerckPre-clinical
26
Comparator: exenatide + Comparator: exenatide + Comparator: PlaceboMerckPhase 1
29
simvastatin/ezetimibe + atorvastatin 20mgMerckApproved
39
sitagliptin phosphate + Comparator: Placebo + Comparator: SitagliptinMerckPhase 2
35
sitagliptin phosphateMerckPhase 1
29
sitagliptin phosphate + Comparator: vogliboseMerckPhase 3
40